An observational study in Cancer Ovaries, Ovarian Mass and Borderline Ovarian Cancer, sponsored by Benha University. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Benha University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Ovarian cancer is frequently diagnosed at an advanced stage, while its early symptoms are often nonspecific . In women presenting with an adnexal mass, clinicians must integrate clinical symptoms, menopausal status, tumour markers, ultrasound findings, cross-sectional imaging, and hereditary risk when deciding whether a patient requires urgent gynaecologic oncology referral, specialist review, additional imaging, or conservative follow-up . Existing validated tools address individual components of this pathway, but these tools and guideline recommendations are distributed across different resources .
CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment . It combines symptom criteria, age-adjusted CA-125 interpretation, HE4/ROMA, Risk of Malignancy Index (RMI), IOTA Simple Rules, O-RADS ultrasound and MRI classification, selected tumour markers, and hereditary risk information. The tool provides a transparent triage category and guideline-based next steps while directing users to established specialist tools where appropriate. CovaRisk is intended to support, rather than replace, clinical judgement and validated specialist models .This study aims to evaluate the diagnostic accuracy of CovaRisk version 1.0 for identifying ovarian malignancy, including borderline tumours, using final histopathology as the reference standard, and to compare its performance with the Risk of Malignancy Index and O-RADS ultrasound classification in the same cohort .This study will be a single-centre retrospective diagnostic accuracy study of women aged 18 years or older who underwent surgery for an adnexal mass and have final histopathology available. Preoperative information will be entered into the frozen CovaRisk version 1.0 without access to the postoperative histopathology result . CovaRisk classification will be compared with final histology as the reference standard. Diagnostic performance will be assessed using sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic curves and area under the curve . CovaRisk will also be compared with RMI and O-RADS ultrasound in the same cohort .The study will provide an objective assessment of whether CovaRisk can accurately identify ovarian malignancy in a real-world hospital population. The findings will guide refinement of the tool and determine whether it is appropriate to proceed to subsequent usability testing and prospective validation.Innovation CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterisation of adnexal masses , standardised imaging risk stratification, and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.
In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide. These features are consistent with the recognised role of clinical decision support systems in standardising care and reducing unwarranted variation in clinical decision-making .
3,385 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
This study's planned enrollment of 320 is above the median of 200 across 616 observational studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women aged 18 years or older who underwent surgery for an adnexal mass at King Faisal Specialist Hospital \& Research Centre, Madinah, Saudi Arabia, between January 2021 and December 2025, and who have final histopathology available. Consecutive eligible cases are identified from operating theatre records and the institutional histopathology database. Included records contain sufficient preoperative information, at least a preoperative ultrasound report or a CA-125 result. Women with previous ovarian cancer are excluded. Data are extracted retrospectively from existing medical records; no participants are recruited or contacted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous ovarian cancer.
A single retrospective cohort of women aged 18 years or older who underwent surgical treatment for an adnexal mass at King Faisal Specialist Hospital \& Research Centre, Madinah. Preoperative clinical, laboratory, imaging, and hereditary risk data are entered into the CovaRisk version 1.0 tool (blinded to final outcomes), and its diagnostic performance is evaluated against final histopathology as the reference standard, alongside comparative assessments using the Risk of Malignancy Index (RMI) and O-RADS ultrasound classification
Other: CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment [9]. It combines symptom criteria, age-adjusted CA-125 interp
This is a retrospective diagnostic accuracy study. These are paired diagnostic assessment methods applied to the same patients, not separate groups receiving different interventions.
Other: CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment [9]. It combines symptom criteria, age-adjusted CA-125 interp
CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population. In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.
Also known as: CovaRisk, TOOL
Sensitivity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy, Including Borderline Tumors, Against Final Histopathology
Proportion of women with a histologically confirmed malignant or borderline ovarian tumour who are classified as high-risk by CovaRisk v1.0. CovaRisk is applied to preoperative data already recorded in medical records, without knowledge of the histopathology result. Reported as a percentage with 95% confidence interval.
Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025
Specificity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy Against Final Histopathology
•Proportion of women with benign final histopathology who are classified as not high-risk (intermediate, low or information-only) by CovaRisk v1.0. Reported as a percentage with 95% confidence interval.
Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025
Positive Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Proportion of women classified as high-risk by CovaRisk v1.0 who have malignant or borderline final histopathology, with 95% confidence interval. Unit: percentage of participants
Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025.
Negative Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy
Proportion of women not classified as high-risk by CovaRisk v1.0 who have benign final histopathology, with 95% confidence interval. Unit: percentage of participants
Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025
No study locations are listed for this record.
Plan to share: No — The document primarily notes that research data will be stored securely on password-protected institutional systems and accessible only to authorized members of the research team in compliance with data-protection requirements.
Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.